May 17, 2020

FDA approves mHealth headband as drug-free migraine remedy

2 min
FDA approves mHealth headband as drug-free migraine remedy.jpg
Written by Alyssa Clark Recently, the Food and Drug Administration recommended and approved a newly developed technology that can set all migraine-suf...

Written by Alyssa Clark


Recently, the Food and Drug Administration recommended and approved a newly developed technology that can set all migraine-suffers at ease, because there proves to be hope after all. With 12 percent of the U.S.’s population suffering from migraines, this problem has been a long-time coming in terms of finding a solution. Finally, this plastic headband-like medical device named Cefaly works to not only treat ongoing migraines, but works to prevent migraines from ever occurring in the first place.  What’s the best thing about this new device? This remedy remains entirely drug free and places the relief of pain onto this new device, rather than onto a pill bottle as we have seen in many years previously. The wave of moving away from traditional prescriptions and heavily-medicated ailments is something we can all be excited about— especially when drug-free remedies such as this become available to the public.

"Cefaly provides an alternative to medication for migraine prevention," said Christy Foreman, director of the Office of Device Evaluation at the FDA's Center for Devices and Radiological Health, according to a news release. "This may help patients who cannot tolerate current migraine medications for preventing migraines or treating attacks."

The headband is built on TENS stimulation, which is described as Transcutaneous electrical nerve stimulation, and works by delivering a small electric current through an electrode on the forehead. The electricity that is pumped to the head stimulates the trigeminal nerve, which has been long tied to being the cause of migraines.

The study found that, “Safety and efficacy for the device was evaluated via a study conducted on 67 people living in Belgium. The participants had two migraine attacks a month and weren't on any medications to prevent headaches. Researchers also looked at data from 2,313 Cefaly users in France and Belgium to assess patient satisfaction.”

Belgium’s STX-Med is the company behind this one-of-a-kind technology, making the headband battery-operated. Cefaly has not only proved to be an example of moving away from the prescription-heavy past, but can now be attained in the U.S. with a prescription from a medical professional.

“Data from the patient satisfaction study showed that over half (53 percent) of the participants were satisfied with the treatment and were willing to buy the device. Common problems of using the device were sleepiness during treatment and headache after treatment session.”


Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article